SG10201914019YA - Antibody producing non-human mammals - Google Patents

Antibody producing non-human mammals

Info

Publication number
SG10201914019YA
SG10201914019YA SG10201914019YA SG10201914019YA SG10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA
Authority
SG
Singapore
Prior art keywords
human mammals
antibody producing
producing non
mammals
antibody
Prior art date
Application number
SG10201914019YA
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Robert Kramer
Kruif Cornelis De
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914019Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG10201914019YA publication Critical patent/SG10201914019YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914019YA 2008-06-27 2009-06-29 Antibody producing non-human mammals SG10201914019YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27

Publications (1)

Publication Number Publication Date
SG10201914019YA true SG10201914019YA (en) 2020-03-30

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Country Status (23)

Country Link
EP (6) EP3456190B1 (ru)
JP (6) JP5749161B2 (ru)
KR (5) KR101990228B1 (ru)
CN (3) CN105191863B (ru)
AU (1) AU2009263082C1 (ru)
CA (1) CA2729095C (ru)
CY (2) CY1114830T1 (ru)
DK (3) DK2556747T3 (ru)
ES (3) ES2445193T3 (ru)
HK (1) HK1154463A1 (ru)
HR (2) HRP20220205T1 (ru)
HU (1) HUE057994T2 (ru)
LT (1) LT3456190T (ru)
MX (1) MX2010014542A (ru)
NZ (1) NZ590118A (ru)
PL (2) PL3456190T3 (ru)
PT (3) PT2556747T (ru)
RS (2) RS53146B (ru)
RU (2) RU2559524C2 (ru)
SG (3) SG10201408500RA (ru)
SI (2) SI3456190T1 (ru)
WO (1) WO2009157771A2 (ru)
ZA (1) ZA201009312B (ru)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK1523496T3 (da) 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EP3456190B1 (en) * 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
EP2421357B1 (en) 2009-07-08 2013-01-23 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
AU2011234988B2 (en) 2010-03-31 2014-10-30 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
SI2739740T1 (sl) * 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102280111B1 (ko) 2011-12-22 2021-07-21 에프. 호프만-라 로슈 아게 발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
RU2683514C2 (ru) * 2012-03-06 2019-03-28 Регенерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
CA2865645A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building
SI2883449T1 (en) 2012-03-16 2018-05-31 Regeneron Pharmaceuticals, Inc. Light-chain modified antibodies with histidine and genetically modified rodents for their production
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP2825035A1 (en) 2012-03-16 2015-01-21 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP3594232A1 (en) 2012-04-20 2020-01-15 Merus N.V. Methods and means for the production of ig-like molecules
EP2854523A1 (en) * 2012-06-05 2015-04-08 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
SG11201506278RA (en) * 2013-03-13 2015-09-29 Regeneron Pharma Mice expressing a limited immunoglobulin light chain repertoire
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
CN109090037B (zh) * 2013-10-15 2021-05-28 瑞泽恩制药公司 人源化的il-15动物
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
RS57928B1 (sr) 2015-07-10 2019-01-31 Merus Nv Antitela koja vezuju humani cd3
US20170058052A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
PL3365373T3 (pl) 2015-10-23 2021-08-23 Merus N.V. Molekuły wiążące, które hamują wzrost nowotworu
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
JP6929877B2 (ja) 2016-02-04 2021-09-01 トリアニ・インコーポレイテッドＴｒｉａｎｎｉ， Ｉｎｃ． 免疫グロブリン産生の増強
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
BR112019002771A2 (pt) 2016-08-12 2019-05-14 Oxitec Ltd polinucleotídeo de módulo de controle de união de doublesex, sistema de expressão de gene, plasmídeo vetor de expressão, inseto geneticamente engenheirado, métodos para produzir insetos geneticamente engenheirados, para cultivar seletivamente insetos macho geneticamente engenheirados, para reduzir uma população de inseto selvagem, para criar um mosquito aedes aegypti transgênico e para detectar a presença de uma molécula de dna, local alvo cromossômico de aedes aegypti, mosquito aedes aegypti geneticamente engenheirado, molécula de dna, e, kit de detecção de dna.
BR112019005895A2 (pt) 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
AU2018239320A1 (en) * 2017-03-20 2019-11-07 Washington University Cells and methods of uses and making the same
KR20190140944A (ko) 2017-03-31 2019-12-20 메뤼스 엔.페. ErbB-2, ErbB-2/ErbB-3 양성 종양을 가진 개체의 치료를 위한, ErbB-2 및 ErbB-3의 세포외 부분 상의 에피토프에 결합하는 항원-결합 부위를 가진 이중특이적 항체 및 ErbB-2 표적화제
CN110650752A (zh) 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
MX2019013804A (es) 2017-05-17 2020-02-24 Merus Nv Combinacion de un anticuerpo biespecifico de erbb-2/erbb-3 con terapia endocrina para cancer de mama.
BR112020000209A8 (pt) 2017-07-06 2020-08-11 Merus Nv moléculas de ligação que modulam uma atividade biológica expressa por uma célula
EP3649155A1 (en) 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
CN117964759A (zh) 2017-07-06 2024-05-03 美勒斯公司 调节由细胞表达的生物活性的抗体
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CN111432838A (zh) 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
ES2928995T3 (es) * 2017-12-05 2022-11-24 Regeneron Pharma Ratones que tienen una cadena ligera lambda de inmunoglobulina genomanipulada y usos de los mismos
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
KR102480493B1 (ko) * 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
MX2020013652A (es) 2018-06-14 2022-04-21 Regeneron Pharma Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
JP2022521036A (ja) 2018-12-20 2022-04-05 メルス ナムローゼ フェンノートシャップ ＣＬＥＣ１２ＡｘＣＤ３二重特異性抗体及び疾患の治療方法
EP3897117A1 (en) 2018-12-21 2021-10-27 Compass Therapeutics LLC Transgenic mouse expressing common human light chain
BR112021013009A2 (pt) 2018-12-31 2021-09-14 Merus N.V. Domínios de ligação mistos
JP7440516B2 (ja) 2018-12-31 2024-02-28 メルス ナムローゼ フェンノートシャップ 切断多価多量体
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
JP2022520649A (ja) 2019-02-14 2022-03-31 メルス ナムローゼ フェンノートシャップ Ｅｇｆｒ、ｈｅｒ２及びｈｅｒ３に結合する結合部分の組み合わせ
US20220127375A1 (en) 2019-02-14 2022-04-28 Merus N.V. Producing compositions comprising two or more antibodies
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
SG11202112399PA (en) 2019-05-09 2021-12-30 Merus Nv Variant domains for multimerizing proteins and separation thereof
CN114502725A (zh) * 2019-07-01 2022-05-13 特里安尼公司 转基因哺乳动物及使用方法
EP3998081A4 (en) * 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
WO2021020416A1 (ja) * 2019-07-30 2021-02-04 小野薬品工業株式会社 二重特異性抗体
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
CN114555115A (zh) 2019-08-19 2022-05-27 美勒斯公司 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
IL294181A (en) 2019-12-24 2022-08-01 Merus Nv tgf-beta-rii binding proteins
CA3166407A1 (en) 2020-01-29 2021-08-05 Merus N.V. Means and method for modulating fimmune cell engaging effects
CA3176186A1 (en) 2020-04-24 2021-10-28 Ernesto Isaac WASSERMAN Treatment of cancers with an antibody that binds lgr5 and egfr
CN115667532A (zh) * 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
CN117624324A (zh) 2020-12-15 2024-03-01 美勒斯公司 利用结合lgr5和egfr的抗体治疗癌症
CN116710486A (zh) 2020-12-16 2023-09-05 美勒斯公司 用于治疗癌症的多特异性抗体
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4262867A1 (en) 2020-12-18 2023-10-25 Merus N.V. Antibody composition
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
WO2023059191A1 (en) 2021-10-06 2023-04-13 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023172134A1 (en) 2022-03-07 2023-09-14 Merus N.V. Treatment with an antibody that binds egfr and cmet.
TW202337909A (zh) 2022-03-07 2023-10-01 荷蘭商美勒斯公司 包括結合EGFR及cMET之抗體的組合療法
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2024136658A1 (en) 2022-12-23 2024-06-27 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) * 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU3328493A (en) * 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
IL138579A0 (en) * 1998-03-30 2001-10-31 Res Dev Foundation Corticotropin releasing factor receptor 1-deficient mice
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1523496T3 (da) * 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
WO2005068622A2 (en) 2004-01-20 2005-07-28 Merus B.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
CA2604440A1 (en) * 2005-04-29 2006-11-09 Inserm (Institut De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3456190B1 (en) * 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
RU2724663C2 (ru) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью

Also Published As

Publication number Publication date
EP2556747A2 (en) 2013-02-13
HK1154463A1 (zh) 2012-04-27
PL2147594T3 (pl) 2014-04-30
ES2445193T3 (es) 2014-02-28
KR20110029156A (ko) 2011-03-22
KR102306491B1 (ko) 2021-09-29
CN105191863A (zh) 2015-12-30
SI3456190T1 (sl) 2022-06-30
RU2020127564A3 (ru) 2022-02-21
JP2017121256A (ja) 2017-07-13
KR20190025068A (ko) 2019-03-08
DK2556747T3 (da) 2021-02-15
EP3456190A1 (en) 2019-03-20
EP3456191A1 (en) 2019-03-20
PT2556747T (pt) 2021-02-15
CN102123582B (zh) 2015-09-30
CY1125119T1 (el) 2023-06-09
KR102112655B1 (ko) 2020-05-19
PT2147594E (pt) 2014-02-17
ES2853226T3 (es) 2021-09-15
CY1114830T1 (el) 2016-12-14
MX2010014542A (es) 2011-04-05
EP3456192A1 (en) 2019-03-20
AU2009263082B9 (en) 2014-07-17
ES2906344T3 (es) 2022-04-18
WO2009157771A3 (en) 2010-02-18
DK2147594T3 (da) 2014-02-10
KR20140127914A (ko) 2014-11-04
HUE057994T2 (hu) 2022-06-28
EP2147594B1 (en) 2013-11-13
DK3456190T3 (da) 2022-02-14
LT3456190T (lt) 2022-03-10
SG10201914027VA (en) 2020-03-30
CN102123582A (zh) 2011-07-13
AU2009263082A1 (en) 2009-12-30
CN105191863B (zh) 2020-12-22
PL3456190T3 (pl) 2022-06-06
JP6824807B2 (ja) 2021-02-03
CA2729095C (en) 2018-12-04
PT3456190T (pt) 2022-02-15
AU2009263082B2 (en) 2014-03-20
JP2022188085A (ja) 2022-12-20
CN112481300A (zh) 2021-03-12
AU2009263082C1 (en) 2018-11-01
EP2556747A3 (en) 2016-08-03
KR20170066688A (ko) 2017-06-14
KR101990228B1 (ko) 2019-06-17
RU2559524C2 (ru) 2015-08-10
JP2011525808A (ja) 2011-09-29
SI2147594T1 (sl) 2014-02-28
CA2729095A1 (en) 2009-12-30
RU2015119670A (ru) 2015-12-10
ZA201009312B (en) 2011-08-31
JP2015156871A (ja) 2015-09-03
JP7242611B2 (ja) 2023-03-20
RU2011102962A (ru) 2012-08-10
EP2147594A1 (en) 2010-01-27
RU2020127564A (ru) 2022-02-21
EP3456190B1 (en) 2021-11-24
RS53146B (en) 2014-06-30
HRP20140139T1 (hr) 2014-03-14
SG10201408500RA (en) 2015-01-29
RU2731084C2 (ru) 2020-08-28
NZ590118A (en) 2012-10-26
HRP20220205T1 (hr) 2022-05-27
EP3456193A1 (en) 2019-03-20
WO2009157771A2 (en) 2009-12-30
JP7439201B2 (ja) 2024-02-27
KR102261586B1 (ko) 2021-06-08
JP2020191882A (ja) 2020-12-03
JP5749161B2 (ja) 2015-07-15
RS62925B1 (sr) 2022-03-31
RU2015119670A3 (ru) 2019-01-22
JP2024063038A (ja) 2024-05-10
KR20200057093A (ko) 2020-05-25
EP2556747B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
HK1154463A1 (zh) 產生抗體的非人哺乳動物
EP2346994A4 (en) NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
ZA201102119B (en) Improved antibody libraies
EP3064512C0 (en) ANTIBODIES AGAINST CLDN6
IL212701A0 (en) Improved anti-cd19 antibodies
HK1158229A1 (en) C-met antibodies c-met
SG10201403703XA (en) Methods of producing humanized non-human mammals
PL2262831T3 (pl) Przeciwciała przeciwko properdynie
GB0821100D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
EP2412808A4 (en) BISPECIFIC ANTIBODY TYPE LH
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
FI20085308A0 (fi) Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
GB0815963D0 (en) Antibody production
GB0820307D0 (en) Antibody production
PL384301A1 (pl) Urządzenie do produkcji biopaliwa
GB0819113D0 (en) An antibody
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody